Market Overview

UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01

Related ACRX
Exclusive: AcelRx Pharma Execs Discuss Stock Performance, Catalysts And Financial Position
AcelRx: Replacing Morphine With Department Of Defense Funding
AcelRx Pharmaceuticals (ACRX) Presents at Family Office & Biotech Investment Symposium (Seeking Alpha)

In a report published Monday, Jefferies analyst Corey Davis initiated coverage on AcelRx Pharmaceuticals (NASDAQ: ACRX) with a Buy rating and $8.00 price target.

In the report, Davis noted, “We expect FDA approval of ACRX's lead product candidate, ARX-01 (a novel sufentanil nanotab PCA system), in 2014 given the solid body of data from Ph2/initial Ph3 success. We see a clear market opportunity for ARX-01 given the current standard of care for post-op pain control is fraught with drawbacks. We forecast $400M peak potential and little threat of generics. Pipeline and partnerships represent upside to our numbers/valuation.”

AcelRx Pharmaceuticals closed on Friday at $4.90.

Latest Ratings for ACRX

May 2016Seaport GlobalUpgradesAccumulateBuy
May 2016H.C. WainwrightMaintainsBuy
Oct 2015JefferiesAssumesBuy

View More Analyst Ratings for ACRX
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Initiation Analyst Ratings


Related Articles (ACRX)

View Comments and Join the Discussion!